# The Evolution of Hypertension Management in Canada: A Review of the Current Guidelines

## TL;DR

This paper reviews how Canadian hypertension guidelines have evolved from 2020 to 2025 to better manage and reduce the risk of cardiovascular disease.

## Contribution

The paper provides a narrative review of updated Canadian hypertension guidelines, emphasizing new treatment thresholds and therapies.

## Key findings

- The new guidelines recommend treating hypertension at a lower blood pressure threshold of ≤130/80 mmHg.
- Single-pill combination medication is now suggested as first-line pharmacological therapy.
- A multidisciplinary approach is emphasized to achieve treatment goals and reduce long-term disease outcomes.

## Abstract

The burden of hypertension has increased in Canada over the last decade and remains a strong risk factor for cardiovascular morbidity and mortality. This has led Hypertension Canada to make it a public health priority and implement multiple strategies from different angles to solve this problem. The guidelines are taking a proactive and aggressive approach to bringing down the rates of hypertension. This narrative review aims to examine the evolution of Canadian hypertension guidelines from 2020 to 2025 and assess how the evidence has informed the updates for the new pharmacological and nonpharmacological interventions for adults over 18 years of age. The databases used were PubMed, Cochrane, and Google Scholar. The types of articles that were included were the Canadian National Hypertension Guidelines, reviews, controlled clinical trial data, and other relevant literature. Adult populations were included, and pediatric populations were excluded. The current guidelines have gained prominence in both clinical and policy discussions. Of note, four major findings were discovered in our review. They aim to have a concise but multidisciplinary approach to treating hypertension to achieve target treatment goals and reduce long-term disease outcomes. The new shift in the guidelines highlights lowering the threshold of treating hypertension at a blood pressure (BP) of ≤130/80 mmHg and the use of single-pill combination medication as first-line pharmacological therapy. Understanding these evolving trends is essential for clinicians and policymakers aiming to optimize patient outcomes and reduce the burden of cardiovascular disease (CVD).